RxDoctor Payments Data

Kenneth Margules, MD

Rheumatology · Libertyville, ILNPI 1063403145

Payments from drug & device makers

$2,336in general payments, 2019–2025

Across 110 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$762
  • Bristol Myers Squibb$150
  • Johnson & Johnson$52
  • Boehringer Ingelheim$48
  • Actelion Pharmaceuticals US, Inc.$41
  • plus $95 from 4 others

What the payments were for

  • Food & beverage$2,23496%
  • Education$1014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie54$1,188
Amgen(2 entities)37$762
Bristol Myers Squibb6$150
Johnson & Johnson(2 entities)3$52
Boehringer Ingelheim2$48
Actelion Pharmaceuticals US, Inc.2$41
Pfizer2$37
GSK2$28
Novartis1$18
Lilly USA, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,336 in reported general payments places this provider in the 55th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$130,138
Medicare patients
140
Services billed
3,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab24$232,854
Humira(Cf) PenAdalimumab12$79,843
ForteoTeriparatide12$52,033
EnbrelEtanercept13$47,126
Leflunomide192$10,762
Pilocarpine Hcl56$5,168
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen228$4,712
Acetaminophen-CodeineAcetaminophen With Codeine266$4,486
Hydroxychloroquine Sulfate125$3,506
Prednisone261$2,272
Fentanyl26$2,175
Tramadol Hcl132$1,514
Sucralfate47$1,095
Sulfasalazine33$1,017
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine26$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo$12$52,03312 claims
AmgenEnbrel$762$47,12613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Libertyville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →